This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Ton Logtenberg, PhD
President and CEO at Merus N.V.


Prof. Ton Logtenberg received his Ph.D. in Immunology from the University of Utrecht. In 1996, he was appointed Professor in Immunology-biotechnology and founded U-BiSys, a biotechnology company that merged with IntroGene to become the publicly-listed company Crucell. In 2006, Ton founded and became the CEO of Merus, a Nasdaq-listed biotechnology company focusing on human bispecific antibodies based on the full length IgG format for the treatment of cancer patients. Ton currently holds a chair in Entrepreneurship in the Life Sciences at Utrecht University.